Literature DB >> 4014173

Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States.

R E Johnson, D N Lawrence, B L Evatt, D J Bregman, L D Zyla, J W Curran, L M Aledort, M E Eyster, A P Brownstein, C J Carman.   

Abstract

The acquired immunodeficiency syndrome (AIDS) was first recognized among hemophiliacs in 1982. The authors have conducted investigations to determine the onset and incidence of AIDS among hemophiliacs and to determine trends in hemophilia mortality since the introduction of clotting-factor concentrates in the late 1960s. A survey of United States hemophilia treatment centers, supported by the Centers for Disease Control and the National Hemophilia Foundation, defined a population of hemophiliacs which was monitored for AIDS cases through June 1984. Death reports from the United States Vital Statistics System and from the hemophilia treatment center survey provided mortality trends for 1968-1979 and for 1978-1982, respectively. The results of these investigations demonstrate the following points. 1) The AIDS epidemic is a new and important cause of illness and mortality among hemophiliacs, although a very low incidence of AIDS among hemophiliacs prior to 1982 cannot be ruled out. 2) The AIDS cases who attended the surveyed hemophilia treatment centers were distributed throughout the United States and were older than hemophilia treatment center patients without AIDS. AIDS cases also used more lyophilized clotting-factor concentrate, but only a small number of cases were reported with this information. 3) Improved care for hemophilia, including the use of clotting-factor concentrates, dramatically reduced hemophilia mortality rates during the 1970s. 4) In 1982, hemorrhage was the major cause of death among hemophiliacs. Deaths from non-alcoholic liver disease were also increased. AIDS incidence among hemophilia treatment center attendees was stable at 0.6 cases per 1,000 hemophilia treatment center attendees per year during 1982 and 1983 but increased sharply to 5.4 cases per 1,000 during the first quarter of 1984.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014173     DOI: 10.1093/oxfordjournals.aje.a114051

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  10 in total

Review 1.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

2.  Natural history of HIV-infection in hemophiliacs: clinical, immunological, and virological findings.

Authors:  T Kamradt; D Niese; K E Schneweis; H H Brackmann; B Kamps; B van Loo; U Hammerstein
Journal:  Klin Wochenschr       Date:  1989-10-17

3.  Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.

Authors:  G D Morse; A Portmore; J Olson; C Taylor; C Plank; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  HIV-1 infection in a cohort of haemophilic patients.

Authors:  N Wagner; R Bialek; H Radinger; M Becker; K E Schneweis; H H Brackmann; D Niese
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

5.  Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85.

Authors:  C Smit; F R Rosendaal; I Varekamp; A Bröcker-Vriends; H Van Dijck; T P Suurmeijer; E Briët
Journal:  BMJ       Date:  1989-01-28

6.  Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom.

Authors:  S C Darby; C R Rizza; R Doll; R J Spooner; I M Stratton; B Thakrar
Journal:  BMJ       Date:  1989-04-22

Review 7.  Factor VIII, HIV and AIDS in haemophiliacs: an analysis of their relationship.

Authors:  E Papadopulos-Eleopulos; V F Turner; J M Papadimitriou; D Causer
Journal:  Genetica       Date:  1995       Impact factor: 1.082

8.  Intravenous immunoglobulin in HIV-I infected haemophilic patients.

Authors:  N Wagner; R Bialek; H Radinger; H H Brackmann; M Becker
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

9.  Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.

Authors:  G D Morse; A C Portmore; V Marder; C Plank; J Olson; C Taylor; W Bonnez; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 10.  Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV.

Authors:  P H Duesberg
Journal:  Genetica       Date:  1995       Impact factor: 1.082

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.